martedì, 1 dicembre 2020
Medinews
8 Gennaio 2018

Japan Approves Pembrolizumab for Urothelial Carcinoma

January 2, 2018 – The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor. The approval is based on the phase III KEYNOTE-045 study, in which single-agent pembrolizumab reduced the risk of death by 27% compared with chemotherapy … (leggi tutto)

TORNA INDIETRO